The hemodynamic response to amrinone in adults is linearly related to A1'vLR concentrations, warranting therapeutic drug monitoring. We report a rapid microsample HPLC method for monitoring AMR and its [AMR; Inocor#{174}; 5 amino-(3, 4'-bipyridine)-6-onel, a bipyridine derivative, is a positive inotrope [1] [2] [3] and vasodilator [4, 5] . 5 Large variability in the blood concentration of AMR and N-acetyl amrinone (N-ac) is related to acetylation genotype:
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Both slow and fast acetylators for amrinone have been identified in the adult population [6] . The therapeutic efficacy [7, 8] Chromatographic conditions. We used a 100 X 2.1 mm C18 (5-gm particles) reversed-phase, narrow-bore colunm (Hewlett-Packard). The mobile phase was 0.1 mol/L phosphate buffer, pH 6.0, and acetonitrile.
The 0.1 molfL phosphate buffer was prepared by mixing 2 L of 0.1 mollL monobasic sodium phosphate with 280 mL of 0.1 mollL dibasic sodium phosphate.
The discontinuous gradient of eluent ranged from 50 to 100 mL/L acetonitrue. Because of variations in the system volumes of different HPLC systems, the time changes for gradient conditions should be optimized for individual systems. We used a flow rate of 0.4 mL/min, each run ending 13.5 mm after sample injection. The temperature was ambient. The dual wavelengths monitored by the DAD were 320 and 345 nm.
Results

AMR and its metabolites
had a greater absorbance at 320 nm and therefore greater sensitivity than at 345 nm. Under the conditions we used, the retention times for AMR, N-gly, and N-ac were 3.7, 7.1, and 8.2 mm, respectively ( Fig. 1 ). Comparing the peak heights of AMR and metabolites at 320 nm with the corresponding peak heights at 345 nm gave ratios of -2.1, 3.3, and 3.3 for AMR, N-gly, and N-ac, respectively.
This ratio depends on the respective compounds' spectra and should be constant, regardless of the concentrations of the compounds. In the presence of coeluting compounds, the peak-height ratios at different wavelengths will vary (depending on the spectra and concentrations of the coeluting compounds), thereby alerting the analyst to the possibility of a coeluting substance.
In the described method, several of the cephalosporins coelute with AMR and metabolites.
For example, cefuroxime elutes under the described chromatographic conditions and is detected at 320 nm but not at 345 nm (Fig. 2) . Monitoring at 345 nm, where cephalosporins do not absorb substantially, allows for the quantification of AMR and metabolites in patients receiving concurrent cephalosporin therapy. We also utilized the DAD to obtain spectral data for AMR and metabolites (Fig. 3) , which might help identify AMR and its metabolites.
Comparing the spectral data of eluting compounds with the spectra obtained for AMR, N-ac, and N-gly calibrators increases confidence as to the identity of the eluting compounds. Spectral analysis was also performed on various cephalosporins. The concentration gradient of acetonitrile allowed separation of AMR and metabolites from salicylate and several cephalosporins (i.e., ceftriaxone). Decreasing the mobile phase solvent strength, by decreasing the quantity of acetonitrile, separated all the cephalosporins tested from AMR and metabolites but substantially lengthened the retention times. This resulted in broader peaks, decreased sensitivity, and lengthy run times. Therefore, we also used the DAD to eliminate the coelution problem. Analytical recovely. The recovery of AMR, N-gly, and N-ac added to specimens to give final serum concentrations of 0.8-100 mg/L was calculated to be 98% ± 2% of measurements We also assayed >30 commonly used medications at drug concentrations greater than the expected maximum blood concentration ( Table 2 ). The cephalosporins were the only coeluting compounds detected. The therapeutic agents listed in Table  2 were assayed according to the above-described analytical conditions and did not interfere with the analysis of AMR and metabolites.
Salicylate elutes and is detected under these conditions; however, its retention time is less than that of AMR and therefore salicylate does not interfere. The corresponding values at 345 nm were very similar to those at 320 nm, with linearity to 100 mgfL for all compounds at both wavelengths.
Precision. The intraday (n = 4) and interday (n = 6) precisions for assaying serum samples containing AMR and metabolites in concentrations of 0.2-50 mgfL are shown in Table 1 a Thesewereeither not detected, were separatedbythe acetonitrile gradient, or were not detectedby monitoring at 345 nm.
Stability. Specimen (serum) stability was tested at various times and storage temperatures, including 4 #{176}C, -20 #{176}C, and -70 #{176}C. AMR concentrations in the serum samples tested ranged between 0.8 and 100 mg/L. Samples were considered stable if their concentrations at reassay were within 5% of their original concentrations for AMR and metabolites. All serum samples tested at the three temperatures were stable for 1 week. By 4 weeks at 4 #{176}C, 60-100% of the AMR had undergone either degradation or metabolism. The breakdown product(s) and metabolite(s) coeluted with N-ac. However, serum samples stored at -20 #{176}C or -70 #{176}C retained the original concentrations (± 5%) of AMR, N-gly, and N-ac throughout the 6-month Table 2 . Drugs assayed by the described method and found not to Interfere with determination of AMR and metabolites.
Cephalosporinsa
Cefuroxime Ceftibuten Cefotaxime testing period. All specimens were stored in the dark because AMR is reported to be sensitive to light (Inocor product insert).
Discussion
During the past 3 years this method has been utilized to measure the serum concentration of AMR and its metabolites in >50 pediatric patients; details on 34 of these patients have been published previously [9, 13] . Fig. 4 demonstrates a representa-,'s rcs
tive chromatograph obtained from a 7-month-old boy with Down syndrome who received a 3 mg/kg loading dose of AMR followed by a constant AMR infusion of 5 tgfkg per minute for 3 days while recovering from a procedure to repair his dysplastic mitral valve. Among other medications, the infant also received ceftazidime during his postoperative course. Fig. 4 shows detection of ceftazidime at 320 nm but not at 345 nm.
Children receiving the same ordered dose of AMR display wide interindividual variation in serum concentrations of the drug [13, 14] .Using the method described here, we measured steady-state serum AMR concentrations ranging from 1.5 to 6.0 ing/L in patients receiving an AMR infusion of 5 j.Lg/kg per minute and from 1.8 to 9.5 mg/L in children receiving an infusion of 10 jLg/kg per minute [13] .This dose-concentration relationship is similar to that obtained previously by a different method [14] .The N-ac concentration also is variable among patients receiving AMR therapy, presumably because different acetylator genotypes are involved. To date, we have not detected the N-gly metabolite in serum from any patient tested in this laboratory.
Cephalosporins
are commonly administered to the patient population receiving AMR. Some cephalosporins also have substantial absorbance at 320 nm but not at 345 nm. One advantage of the DAD is that it is able to ratio the peak heights at two different wavelengths, which can alert the investigator to the presence of coeluting compounds.
Once one is aware of coeluting compounds, the peak measured at 345 nm can be used to calculate the AMR and metabolite concentrations. Although monitoring at 345 nm is not optimal for AMR and metabolites, it allows for quantification, reliably detects concentrations as low as 0.5 mg/L, and utilizes the same methods for sample preparation and HPLC injection, while avoiding cephalosporin interference.
The cephalosporin interference has not been addressed by other reported methods [14] [15] [16] .
The concentration gradient of acetonitrile in the mobile phase achieved separation of AMR and metabolites from salicylate and some cephalosporins.
Altering the mobile phase, by decreasing solvent strength enough to separate all the cephalosporins tested from AMR and metabolites, substantially delays the retention times. This results in prolonged assay time, broader peaks, and therefore decreased sensitivity. Thus, use of the DAD proved to be a more useful way to eliminate a coelution problem. Using a gradient system decreased the peak width of later-eluting peaks, which increased assay sensitivity while separating AMR and metabolites from each other and some cephalosporins. It is customary to use an internal standard with chromatographic methods.
However, in view of the simplicity of the sample preparation and the demonstrated precision, the use of external standards in the described method is appropriate.
Evaluation of the precision for individual HPLC systems should be performed to determine whether external calibration curves would be appropriate for each laboratory.
If not, an internal standard should be added to the acetonitrile before the sample preparation.
\'Ve conclude that this method provides an accurate, rapid, and sensitive assay for AMR and metabolites.
The precision and recovery for AMR and metabolites from a biological matrix are excellent. Other advantages of this method include rapid sample preparation, without the need for a sample concentrating step or a lengthy extraction procedure as required in other methods [15] .The small sample volume, as little as 50 ML, is a distinct advantage for both therapeutic drug monitoring and clinical trials in the pediatric patient population.
This HPLC micromethod has the sensitivity and linearity necessary for monitoring patients throughout the therapeutic range. Finally, the described method has also been used to analyze specimens from various animal models, including piglets, canines, and rats.
